MiR126-Targeted-Nanoparticles Combined with PI3K/AKT Inhibitor as a New Strategy to Overcome Melanoma Resistance

Scientists synthesized chitosan nanoparticles containing a chemically modified miR126 sequence, which were further functionalized with an antibody specific to the chondroitin sulfate proteoglycan 4 melanoma marker.